Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own0.40% Shs Outstand36.89M Perf Week-0.36%
Market Cap204.69M Forward P/E- EPS next Y-3.73 Insider Trans0.00% Shs Float36.87M Perf Month-27.16%
Income-91.00M PEG- EPS next Q-0.69 Inst Own83.00% Short Float3.77% Perf Quarter-51.07%
Sales27.70M P/S7.39 EPS this Y3.90% Inst Trans0.08% Short Ratio3.53 Perf Half Y-54.64%
Book/sh0.98 P/B5.58 EPS next Y-27.90% ROA-64.80% Target Price30.11 Perf Year-68.40%
Cash/sh- P/C- EPS next 5Y20.00% ROE-145.50% 52W Range4.19 - 19.83 Perf YTD-53.96%
Dividend- P/FCF- EPS past 5Y14.50% ROI-107.70% 52W High-72.42% Beta1.54
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin95.80% 52W Low30.55% ATR0.52
Employees113 Current Ratio6.90 Sales Q/Q688.90% Oper. Margin- RSI (14)39.44 Volatility9.02% 9.90%
OptionableYes Debt/Eq1.94 EPS Q/Q29.20% Profit Margin- Rel Volume0.43 Prev Close5.32
ShortableYes LT Debt/Eq1.94 EarningsMay 12 AMC Payout- Avg Volume394.42K Price5.47
Recom1.50 SMA20-8.04% SMA50-28.44% SMA200-47.20% Volume170,772 Change2.82%
Sep-30-20Initiated Truist Buy $35
Jul-01-20Reiterated H.C. Wainwright Buy $6 → $9
Jul-01-20Initiated Cowen Outperform
Apr-09-20Initiated Craig Hallum Buy $4.50
Dec-20-19Initiated Oppenheimer Outperform
Mar-05-19Resumed Jefferies Buy $3.50 → $10
Feb-27-19Downgrade Mizuho Buy → Neutral $13 → $5
Feb-06-19Initiated Leerink Partners Outperform $10
Jul-02-18Initiated Cantor Fitzgerald Overweight $19
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
May-18-22 09:00AM  
May-12-22 05:35PM  
May-10-22 05:00PM  
May-05-22 06:05PM  
Apr-20-22 07:30AM  
Apr-18-22 04:30PM  
Apr-14-22 07:00AM  
Mar-31-22 08:18AM  
Mar-27-22 01:08PM  
Mar-21-22 09:52AM  
Mar-18-22 02:44PM  
Mar-15-22 04:30PM  
Mar-10-22 08:05AM  
Mar-01-22 07:25PM  
Feb-28-22 05:35PM  
Feb-23-22 07:15AM  
Feb-22-22 04:01PM  
Feb-16-22 07:00AM  
Feb-14-22 01:31PM  
Feb-10-22 05:00PM  
Feb-03-22 07:30AM  
Jan-21-22 01:38PM  
Jan-18-22 02:57PM  
Jan-14-22 05:00PM  
Jan-05-22 07:30AM  
Dec-03-21 10:01AM  
Nov-15-21 07:30AM  
Nov-09-21 08:15AM  
Nov-08-21 05:00PM  
Oct-26-21 07:30AM  
Oct-25-21 08:38AM  
Oct-15-21 09:56AM  
Oct-08-21 04:31PM  
Oct-05-21 07:30AM  
Sep-28-21 04:01PM  
Sep-20-21 07:30AM  
Sep-14-21 10:15AM  
Sep-09-21 04:30PM  
Aug-26-21 07:30AM  
Aug-25-21 04:30PM  
Aug-18-21 07:37AM  
Aug-17-21 04:01PM  
Aug-16-21 11:44AM  
Aug-10-21 08:15AM  
Aug-06-21 05:00PM  
Aug-03-21 04:00PM  
Jul-27-21 07:00PM  
Jul-16-21 09:07AM  
Jul-09-21 09:12AM  
Jul-01-21 08:00AM  
Jun-22-21 05:00PM  
Jun-21-21 09:04AM  
Jun-15-21 04:55AM  
Jun-14-21 05:02PM  
Jun-11-21 07:30AM  
Jun-04-21 09:04AM  
May-17-21 08:55AM  
May-13-21 02:30PM  
May-07-21 07:57AM  
Apr-28-21 04:30PM  
Apr-16-21 05:50AM  
Apr-12-21 05:30PM  
Mar-24-21 09:00AM  
Mar-09-21 08:55AM  
Feb-23-21 07:00AM  
Feb-17-21 07:00AM  
Feb-15-21 01:57AM  
Feb-12-21 04:01PM  
Feb-10-21 07:31AM  
Jan-28-21 12:13PM  
Jan-26-21 07:01AM  
Jan-14-21 10:46AM  
Jan-13-21 07:01AM  
Jan-06-21 07:02AM  
Jan-04-21 09:27AM  
Dec-21-20 07:02AM  
Dec-14-20 11:39AM  
Dec-08-20 06:20PM  
Dec-07-20 04:01PM  
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.